177 related articles for article (PubMed ID: 8588056)
1. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam.
Bourin M; Malinge M
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):567-75. PubMed ID: 8588056
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders].
Lemoine P; Rouillon F; Pouget D
Encephale; 1996; 22(6):461-7. PubMed ID: 10901839
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study.
Delle Chiaie R; Pancheri P; Casacchia M; Stratta P; Kotzalidis GD; Zibellini M
J Clin Psychopharmacol; 1995 Feb; 15(1):12-9. PubMed ID: 7714222
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
Lemoine P; Touchon J; Billardon M
Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
Cutler NR; Sramek JJ; Keppel Hesselink JM; Krol A; Roeschen J; Rickels K; Schweizer E
J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
[TBL] [Abstract][Full Text] [Related]
6. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients.
Laakmann G; Schüle C; Lorkowski G; Baghai T; Kuhn K; Ehrentraut S
Psychopharmacology (Berl); 1998 Apr; 136(4):357-66. PubMed ID: 9600581
[TBL] [Abstract][Full Text] [Related]
7. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study.
Cohn JB; Wilcox CS
J Clin Psychiatry; 1986 Aug; 47(8):409-12. PubMed ID: 2874128
[TBL] [Abstract][Full Text] [Related]
8. Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone.
Petracca A; Nisita C; McNair D; Melis G; Guerani G; Cassano GB
J Clin Psychiatry; 1990 Sep; 51 Suppl():31-9. PubMed ID: 2211564
[TBL] [Abstract][Full Text] [Related]
9. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects.
Busto UE; Naranjo CA; Bremner KE; Peachey JE; Bologa M
J Psychiatry Neurosci; 1998 Jan; 23(1):35-44. PubMed ID: 9505058
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
Cutler NR; Sramek JJ; Wardle TS; Hesselink JM; Roeschen JK
Psychopharmacol Bull; 1993; 29(2):303-8. PubMed ID: 7904761
[TBL] [Abstract][Full Text] [Related]
11. Comparison of withdrawal of buspirone and diazepam: a placebo controlled study.
Fontaine R; Beaudry P; Beauclair L; Chouinard G
Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(2-3):189-97. PubMed ID: 2888159
[TBL] [Abstract][Full Text] [Related]
12. Controlled comparison of buspirone and oxazepam in generalized anxiety.
Ansseau M; Papart P; Gérard MA; von Frenckell R; Franck G
Neuropsychobiology; 1990-1991; 24(2):74-8. PubMed ID: 2134114
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone.
Rickels K; Schweizer E; Csanalosi I; Case WG; Chung H
Arch Gen Psychiatry; 1988 May; 45(5):444-50. PubMed ID: 2895993
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety.
Sramek JJ; Frackiewicz EJ; Cutler NR
Clin Ther; 1997; 19(3):498-506. PubMed ID: 9220214
[TBL] [Abstract][Full Text] [Related]
15. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy.
Rickels K; DeMartinis N; García-España F; Greenblatt DJ; Mandos LA; Rynn M
Am J Psychiatry; 2000 Dec; 157(12):1973-9. PubMed ID: 11097963
[TBL] [Abstract][Full Text] [Related]
16. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder.
Kasper S; Iglesias-García C; Schweizer E; Wilson J; DuBrava S; Prieto R; Pitman VW; Knapp L
Int J Neuropsychopharmacol; 2014 May; 17(5):685-95. PubMed ID: 24351233
[TBL] [Abstract][Full Text] [Related]
17. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
Pollack MH; Worthington JJ; Manfro GG; Otto MW; Zucker BG
J Clin Psychiatry; 1997; 58 Suppl 11():19-23. PubMed ID: 9363044
[TBL] [Abstract][Full Text] [Related]
18. Clorazepate and lorazepam: clinical improvement and rebound anxiety.
Rickels K; Fox IL; Greenblatt DJ; Sandler KR; Schless A
Am J Psychiatry; 1988 Mar; 145(3):312-7. PubMed ID: 2894175
[TBL] [Abstract][Full Text] [Related]
19. Nonorganic insomnia in generalized anxiety disorder. 2. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods.
Saletu B; Saletu-Zyhlarz G; Anderer P; Brandstätter N; Frey R; Gruber G; Klösch G; Mandl M; Grünberger J; Linzmayer L
Neuropsychobiology; 1997; 36(3):130-52. PubMed ID: 9313245
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effectiveness of Galphimia glauca vs. lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial.
Herrera-Arellano A; Jiménez-Ferrer JE; Zamilpa A; García-Alonso G; Herrera-Alvarez S; Tortoriello J
Planta Med; 2012 Sep; 78(14):1529-35. PubMed ID: 22828921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
